This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168–81.
Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132–43.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl J Med. 2004;350:114–24.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European. LeukemiaNet Leuk. 2018;32:1057–69.
National Comprehensive Cancer Network. Myeloproliferative Neoplasms (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed August 10, 2020.
Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174:382–96.
Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111:3383–7.
Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592–2601.
Barbui T, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Gemelli IRCCS A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Artic Lancet Haematol. 2021;8:175–84.
Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;2:403.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–e208.
Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107:451–8.
Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30.
Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer. 2017;123:449–58.
Acknowledgements
This study was supported by grants from the David L. Johns Family of the Cancer Research & Treatment Fund (CR&T) and MPN Peoria.
Author information
Authors and Affiliations
Contributions
GAZ/JMS/RTS wrote the manuscript. GAZ/JMS designed and performed the statistical analysis. KAZ collected and analyzed data.
Corresponding author
Ethics declarations
Competing interests
GAZ—Advisory board, PharmaEssentia. RTS—Speaker bureau and consultant, PharmaEssentia. KAZ—None. JMS—Research support and advisory board, Abbvie.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Abu-Zeinah, G., Silver, R.T., Abu-Zeinah, K. et al. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia 36, 569–572 (2022). https://doi.org/10.1038/s41375-021-01447-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01447-3
This article is cited by
-
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Annals of Hematology (2024)
-
Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival
Leukemia (2023)
-
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
Leukemia (2023)
-
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Leukemia (2023)
-
Essenzielle Thrombozythämie und Polycythaemia vera
Die Onkologie (2023)